Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care

Fresenius Medical Care (NYSE:FMS) reported a milestone year with higher profitability and strong shareholder returns.

Rhea-AI Summary

Fresenius Medical Care (NYSE:FMS) reported a milestone year with higher profitability and strong shareholder returns. Organic revenue grew 8% at constant currency and the adjusted group operating margin reached 11.3%, up from 7.9% three years earlier.

Net leverage fell to 2.5x from 3.4x in 2022. Shareholders approved a higher dividend of EUR 1.49 per share and the company completed a EUR 1 billion buyback, repurchasing 24.8 million shares (8.5% of share capital) in under one year.

The AGM also granted a new five‑year authorization for further share repurchases and highlighted FDA approval and the 2026 U.S. launch of the 5008X CAREsystem, supporting the FME Reignite strategy through 2030.

Positive

• Organic revenue growth of 8% at constant currency in 2025
• Adjusted group operating margin increased to 11.3% from 7.9% over three years
• Net leverage ratio reduced to 2.5x from 3.4x in 2022
• Dividend raised to EUR 1.49 per share for fiscal 2025
• Completed EUR 1.0 billion buyback, retiring 24.8M shares (8.5% of share capital)
• New 5‑year authorization for further treasury share buybacks approved with 97.59% support
• FDA approval and 2026 U.S. launch of 5008X CAREsystem for high‑volume hemodiafiltration

Negative

• None.

Argus May 21 session

+1.35% close to close Open Argus

Details

News Market Reaction – FMS

On May 21, the day this news came out, FMS closed 1.35% above the previous close.

Data tracked by StockTitan Argus for the May 21 session.

Key Figures

Dividend per share: EUR 1.49 Dividend payout ratio: 30–40% Organic revenue growth: 8% +5 more

Dividend per share

EUR 1.49

Dividend for fiscal year 2025 (prior year EUR 1.44)

Dividend payout ratio

30–40%

Target payout ratio of net income excluding special items

Organic revenue growth

8%

Organic revenue growth over the past year at constant currency

Operating margin

11.3%

Group operating margin in 2025, up from 7.9% three years ago

Net leverage ratio

2.5x

Net leverage at end of 2025, down from 3.4x in 2022

Share buyback size

EUR 1.0 billion

Initial share buyback program completed by April 30, 2026

Shares repurchased

24.8 million

Shares bought back, representing 8.5% of share capital

AGM participation

78.71%

Portion of share capital represented at the Annual General Meeting

Historical Context

5 past events · Latest: May 20

5 events

1. May 20

   CFO reappointment

   24h Move

   +0.3%

   Extended CFO term to 2031, supporting governance and strategic continuity.

2. May 05

   Q1 2026 results

   24h Move

   -10.9%

   Mixed Q1 results with organic growth but lower reported earnings from one-time costs.

3. Feb 24

   2025 earnings, buyback

   24h Move

   -7.8%

   Strong 2025 earnings, higher margins, major savings and new €1.0bn buyback.

4. Jan 15

   Home dialysis update

   24h Move

   +1.1%

   Growth in U.S. home hemodialysis and launch of VersiHD with GuideMe software.

5. Jan 09

   Buyback acceleration

   24h Move

   +1.4%

   Acceleration of second tranche of €1.0bn buyback under FME Reignite framework.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hemodiafiltration, dialysis, net leverage ratio, treasury shares, +1 more

5 terms

hemodiafiltration medical

"approval of our hemodiafiltration‑capable 5008X CAREsystem in the United States."

A blood-cleaning treatment for people whose kidneys fail that combines two actions — one that washes away small dissolved wastes and another that filters out larger particles and excess fluid — using a machine and a sterile replacement fluid. It matters to investors because adoption of this technique affects demand for dialysis machines, disposable supplies, treatment costs and patient outcomes, so shifts in use can change revenues and clinical competitiveness like an equipment upgrade improving both speed and results.

dialysis medical

"More than 44 million dialysis treatments delivered worldwide, and life-sustaining medical technology..."

Dialysis is a medical treatment that cleans the blood and removes extra fluid when the kidneys can no longer do that job, using a machine or a filtered solution much like an external water filter for the body. It matters to investors because dialysis creates steady demand for specialized clinics, machines, supplies and drugs, driving predictable revenue streams, capital and regulatory risks, and long-term patient volumes that affect healthcare company valuations.

net leverage ratio financial

"we reduced our net leverage ratio to 2.5 times down from 3.4 times in 2022."

The net leverage ratio measures how much debt a company has compared to its available assets or earnings, after accounting for its cash and liquid assets. It helps investors understand how heavily a company relies on borrowed money to finance its operations and growth. A higher ratio indicates greater financial risk, while a lower ratio suggests a more cautious approach to borrowing.

treasury shares financial

"granted the Management Board a new authorization to acquire and use treasury shares..."

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

share buyback program financial

"EUR 1 billion share buyback program successfully completed, and a new authorization granted..."

A share buyback program is when a company uses its cash to repurchase its own outstanding shares from the market, reducing the number of shares available to investors. That matters because it can raise the value of remaining shares and signal management's confidence in the business—similar to a bakery buying back unsold loafs to make each remaining loaf represent a larger share of its oven’s output—though buybacks can also affect cash available for other uses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Shareholders approve proposed dividend of EUR 1.49 per share
• FME Reignite strategy launched in 2025 successfully drives the next phase of value creation
• 5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026
• EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company's capital allocation framework which includes share buyback programs

BAD HOMBURG, Germany, May 21, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in profitability. Over the past three years, the Company has successfully delivered on its mid‑term financial and strategic targets set for 2025. Building on this transformation, Fresenius Medical Care is now focused on executing its FME Reignite strategy and advancing sustainable value creation.

At today's Annual General Meeting, Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care AG, said, "We are firmly operating in a new time, defined by geopolitical uncertainty, transactional global relationships, and market volatility. For a global healthcare company such as Fresenius Medical Care, adaptability is decisive. The ability to recognize changes early on and anticipate them will be essential for success. For this, the Company laid the groundwork last year."

Michael Sen added, "Fresenius Medical Care looks back on a strong year. Financial performance and margins have improved, and leverage has been reduced. Organic revenue growth reached 8 percent¹, driven by positive contributions from all operating segments. On behalf of the Supervisory Board, I thank the Management Board, under the leadership of Helen Giza, and all 110,000 employees of Fresenius Medical Care for their performance. More than 44 million dialysis treatments delivered worldwide, and life-sustaining medical technology supplied to patients in 140 countries are impressive figures. The Company did a lot of things right last year and is now well-positioned. I am confident that Fresenius Medical Care will continue to provide top-tier kidney care in the future while also achieving financial success."

Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said, "2025 marked the culmination of our FME25 turnaround and transformation, a multi-year effort to fundamentally strengthen Fresenius Medical Care. Despite a challenging external environment, we set out to make this Company healthier, more resilient, and more disciplined. I am proud to say that we delivered, and that we have the aspiration to lead kidney care through exceptional patient care and innovation. We closed 2025 at the upper end of our outlook, with solid revenue results and strong operating income growth. Our group operating margin² increased to 11.3 percent, up from 7.9 percent just three years ago; firmly within our mid‑term target range of 10 to 14 percent. By the end of last year, we reduced our net leverage ratio to 2.5 times down from 3.4 times in 2022."

Helen Giza added, "Equally important, we reached a major milestone in 2025 with the U.S. Food and Drug Administration approval of our hemodiafiltration‑capable 5008X CAREsystem in the United States. This approval enabled the introduction of high‑volume hemodiafiltration therapy in select U.S. clinics, laying the groundwork for the full commercial launch that is currently underway in 2026. We are launching this therapy in the U.S. from a strong foundation. In the United States, nearly 90% of in‑center dialysis machines are Fresenius Medical Care devices. The transition to the 5008X CAREsystem will be the largest infrastructure upgrade in our Company's history – and a defining moment for kidney care in the U.S."

"Everything we do must serve the people who depend on us: patients and their loved ones," said Giza. "At our Capital Markets Day in June 2025, we introduced FME Reignite – our five‑year strategy through 2030. Our ambition is clear: We strive to deliver industry‑leading outcomes, generate margins with above-market growth, and drive value creation. We have the science, the systems, and the people to deliver." The CEO thanked employees for their dedication and commitment to ensuring high-quality care for patients worldwide.

A majority of 99.87 percent of the votes cast at the Annual General Meeting approved the dividend proposal for fiscal year 2025 of EUR 1.49 per share entitled to dividend (2024: EUR 1.44 per share).  Fresenius Medical Care's dividend policy foresees a stable and predictable dividend development, resulting in a 30 to 40 percent payout ratio of net income³.

As part of the capital allocation framework, shareholder returns through dividends are complemented by share buybacks. Under an initial €1.0 billion share buyback program, 24.8 million shares – representing 8.5% of the share capital – were repurchased in a significantly accelerated manner. On April 30, 2026, the share buyback program, consisting of two tranches, was successfully completed in under one year, instead of the originally announced two‑year period.

With a majority of 97.59 percent, the Annual General Meeting granted the Management Board a new authorization to acquire and use treasury shares for a period of five years. This renewed authorization is intended to support the FME capital allocation framework, which includes share buyback programs to continue shareholder value creation.

The Annual General Meeting approved the Compensation Report for the Management Board and the Supervisory Board for fiscal year 2025 with a majority of 84.67 percent.

The actions of the Management Board and the Supervisory Board for 2025 were formally approved by majorities of 99.87 percent and 97.42 percent, respectively.

Further details on the voting results for these and other agenda items will be published on the Company's website.

At the Annual General Meeting, 78.71 percent of the share capital was represented.

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

¹ At constant currency, adjusted for certain reconciling items including revenue from acquisitions, closed or sold operations and differences in dialysis days
² Adjusted for special items
³ Net income attributable to shareholders of FME AG excluding special items

Media Contact
Christine Peters 
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com 

Sven Jacobsen
T +49 171 28 79 127
sven.jacobsen@freseniusmedicalcare.com 

Contact for Analysts and Investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com 

www.freseniusmedicalcare.com/de

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-annual-general-meeting-strengthening-performance-and-advancing-innovation-in-kidney-care-302779080.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What dividend did Fresenius Medical Care (FMS) approve at its 2026 AGM?

Fresenius Medical Care shareholders approved a dividend of EUR 1.49 per share for fiscal 2025. According to Fresenius Medical Care, this continues its policy of stable, predictable dividends targeting a 30–40% payout ratio of adjusted net income.

How did Fresenius Medical Care (FMS) perform financially in 2025?

Fresenius Medical Care reported organic revenue growth of 8% at constant currency in 2025. According to Fresenius Medical Care, the adjusted group operating margin rose to 11.3%, up from 7.9% three years earlier, and the net leverage ratio improved to 2.5x.

What does the EUR 1 billion share buyback mean for Fresenius Medical Care (FMS) investors?

Fresenius Medical Care completed a EUR 1.0 billion buyback, repurchasing 24.8 million shares. According to Fresenius Medical Care, these shares equal about 8.5% of share capital and were bought back in under one year, supporting its capital allocation framework and shareholder value plans.

What new share repurchase authorization did Fresenius Medical Care (FMS) receive in May 2026?

The AGM granted Fresenius Medical Care a new five‑year authorization to acquire and use treasury shares. According to Fresenius Medical Care, 97.59% of votes supported this mandate, which is intended to back its capital allocation framework, including future share buyback programs.

Why is the 5008X CAREsystem FDA approval important for Fresenius Medical Care (FMS)?

FDA approval enables U.S. use of the hemodiafiltration‑capable 5008X CAREsystem, with full launch underway in 2026. According to Fresenius Medical Care, this will support the largest infrastructure upgrade in its history and expand high‑volume hemodiafiltration therapy in U.S. clinics.

What is the FME Reignite strategy mentioned by Fresenius Medical Care (FMS)?

FME Reignite is Fresenius Medical Care’s five‑year strategy running through 2030. According to Fresenius Medical Care, it aims to deliver industry‑leading outcomes, achieve margins with above‑market growth, and drive value creation through disciplined operations and innovation in kidney care.

What voting results and participation were reported at the Fresenius Medical Care (FMS) 2026 AGM?

At the AGM, 78.71% of share capital was represented, indicating strong participation. According to Fresenius Medical Care, dividend approval reached 99.87% support, Management Board actions 99.87%, Supervisory Board actions 97.42%, and the Compensation Report was approved by 84.67% of votes.